mercredi 14 août 2019

Onco Actu du 14 août 2019

Pour information : les publications d'Onco Actu s'interrompent aujourd'hui, elles reprendront à partir du 2 septembre.


New Study Helps to Understand Human Defence Mechanisms and Spread of Cancer [University of Turku]
Led by Jalkanen, the research group analysed the lymphatic vasculature of the human lymph nodes with the help of single-cell sequencing and found six different groups of lymphatic vessels that are situated at strategic spots in the lymph nodes and express molecules typical of each group.


Improving the Quality of Dietary Research [JAMA]
Compared with pharmaceutical research, studies evaluating diet or dietary interventions for chronic diseases like obesity (to be distinguished from micronutrient deficiency syndromes like scurvy or rickets) have far greater challenges in terms of consistency, quality control, confounding, and interpretation.


Teen vaping tied to marijuana use [Reuters]
Adolescents and young adults who have smoked e-cigarettes are more than three times more likely to move on to marijuana than youth who never try vaping, a research review study suggests.

‘Juul-alikes’ Are Filling Shelves With Sweet, Teen-Friendly Nicotine Flavors [NY Times]
After Juul Labs, under pressure from the Food and Drug Administration, stopped selling most of its hugely popular flavored nicotine pods in stores last fall, upstart competitors swooped in to grab the shelf space.


Complex Genetic Testing Errors Emerge Amid Increasing Panel Use, Consumer Access, Case Series Finds [Genome Web]
Errors in the ordering and interpretation of genetic tests for cancer, as well as in communicating results, are continuing to occur, and a newly published report highlighting some of these errors suggests that the nature of the mistakes are reflective of the rapid growth in the market — particularly with next-generation sequencing panels — and increasing consumer access through direct-to-consumer offerings.


Lynparza Phase III PAOLA-1 trial met primary endpoint as 1st-line maintenance treatment with bevacizumab for advanced ovarian cancer [AstraZeneca]
The trial met its primary endpoint in the intent-to-treat* population with a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS), increasing the time women taking Lynparza plus bevacizumab lived without disease progression or death vs. those taking bevacizumab alone.


Collaboration aims to discover new immuno-oncology targets [Harvard]
Harvard, Merck to collaborate on research led by Harvard immunologist Arlene Sharpe, seeking to identify new pathways for the treatment of cancer.


Deciphera shares skyrocket as cancer drug improves progression-free survival [Reuters]
The treatment, ripretinib, was tested against placebo in 129 patients with advanced gastrointestinal stromal tumors (GIST), a rare cancer affecting the digestive tract, who had received at least 3 prior therapies.

Deciphera Pharmaceuticals Reports Positive Updated Phase 1 Data for Ripretinib in Gastrointestinal Stromal Tumors [Deciphera]
Data from Phase 1 Study Supports Ongoing INTRIGUE Phase 3 Clinical Study in Patients with Second-line GIST.

Little Deciphera will hustle positive PhIII survival data on lead cancer drug to the FDA in search of its first OK — shares soar [EndPoints]
On that PFS rate, investigators reported back a median of 6.3 months for the drug arm compared to only 1 month in the control group. That left a hazard ratio of 0.15 — very good, though the PFS itself is not overly impressive — with a solidly positive p-value.

Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug [Xconomy]
Deciphera and rival Blueprint Medicines are both trying to bring newer, similar kinase inhibitors into the mix. They have started by testing their drugs in patients who have failed Gleevec, Sutent, and Stivarga, and both have plans to move those drugs into earlier stages of testing.

Deciphera success sets up 2-horse race in gastrointestinal cancer [Biopharma Dive]
Deciphera shares rose by more than 80% Tuesday, adding more than $600 million to the biotech's valuation.

Deciphera soars as phase 3 cancer data tee up FDA filing [Fierce Biotech]
Other parts of the data are less positive. Deciphera missed the key secondary endpoint of objective response rate, numerically outperforming placebo by 9.4% to zero percent but falling just short statistically.


History of the Growing Burden of Cancer in India: From Antiquity to the 21st Century [Journal of Clinical Oncology]
India’s current burden of a million incident cancers is the result of an epidemiologic transition, improved cancer diagnostics, and improved cancer data capture. The increase in cancer in India with wide interstate variations offers useful insights and important lessons for developing countries in managing their increasing cancer burdens.

Risks for Patients with Pre-existing Conditions on Novel Prostate Cancer Therapies [Thomas Jefferson University]
Common prostate cancer therapy may increase short-term risk of death in patients with pre-existing cardiovascular conditions.

MGUS to Myeloma: Study Suggests Risk of Progression Can Change [NCI]
Currently, only people who have a high- or intermediate-risk MGUS are recommended to receive annual follow-up tests to check for signs of progression. However, the study investigators said that their findings support annual blood tests for all individuals with MGUS, regardless of their initial risk assessment.


The Oncologist’s Wager [Journal of Clinical Oncology]
I believe that it is time to address factors other than “the evidence” that routinely affect decision making in our daily practices. The focus of this essay is on adjuvant therapy, but the concepts apply broadly to our decision making.


A standardized citation metrics author database annotated for scientific field [PLOS BIOLOGY]
We have created a publicly available database of 100,000 top scientists that provides standardized information on citations, h-index, coauthorship-adjusted hm-index, citations to papers in different authorship positions, and a composite indicator. Separate data are shown for career-long and single-year impact.


Artificial Intelligence labs, immigration and NHS funding: what do the latest Government announcements mean for cancer? [Cancer Research UK]
The last few weeks have seen some encouraging announcements from the new Government, but there’s much more to do. And as our chief executive writes, diagnosing cancer early should be at the top of their list.


Trump’s Canada Drug Import Plan Can’t Happen Without Big Pharma [Bloomberg]
Selling outside of Canada wouldn’t serve the wholesalers’ customers and could put them at risk of being cut off by the manufacturers, he said. Exporting in bulk requires a license from Health Canada -- something that typically only happens during humanitarian aid efforts, he said.


Drinking Bleach Won’t Cure Cancer or Anything Else, F.D.A. Says [NY Times]
Alarmed about misinformation online, the agency warned about bleach solutions that are being marketed as cures for autism, H.I.V./AIDS and cancer.